NCT05156970View on ClinicalTrials.gov

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2025

Conditions
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Camrelizumab

Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months

DRUG

Cisplatin

Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)

DRUG

Docetaxel

Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)

DRUG

Apatinib Mesylate

Apatinib 250mg qd for up to 24 months

DRUG

Carboplatin

Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)

Trial Locations (1)

86

the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER